PDCD1 and neoplasm: Evidence suggests that targeting both tumor vessels and immune cells could increase their effectiveness in cancer patients.[3] Studies have confirmed that the combination of anti-angiogenesis therapy and anti-PD1/PDL1 develops a positive reinforcing feedback loop to normalize tumor blood vessels, relieve hypoxia via increased tumor perfusion, and enhance the activation and infiltration of effector T cells, thus providing survival benefits.[4] Currently, the National Comprehensive Cancer Network recommends combination therapy as a treatment for multiple solid cancers.